Comorbidities and Survival Risk Measures of Pulmonary Hypertension (PH) Patients in US-Clinical Care: Real-World Assessments from the Trio Health PH Registry


Chakinala MM1, Rane D2, Oudiz RJ3, Frost AE4, Frantz RP5, Nathan SD6, Farber HW7
1Washington University School of Medicine in St. Louis, St. Louis, MO, USA, 2Trio Health, Louisville, CO, USA, 3Liu Center for Pulmonary Hypertension, Lundquist Institute for Biomedical Innovation at Harbor – UCLA Medical Center, Los Angeles, CA, USA, 4Institute of Academic Medicine, Houston Methodist, Houston, TX, USA, 5Mayo Clinic College of Medicine, Rochester, MN, USA, 6Inova Fairfax Hospital, Falls Church, VA, USA, 7Tufts Medical Center, Boston, MA, USA

Presentation Documents


TRIO Health PH registry differentiates from existing registry populations (COMPERA/ASPIRE/REVEAL) in consisting of patients managed in the modern era.


TRIO Health PH registry contains retrospective clinical and prescription data from eight US tertiary care centers. Descriptive and statistical analyses (ANOVA, Tukey’s studentized range procedure, Chi-square or Fisher’s exact test) were conducted for 725/1000 registry patients, enrolled July 2019-October 2020, among group 1 - pulmonary arterial hypertension (PAH) and group 4 - chronic thromboembolic pulmonary hypertension (CTEPH).


Study etiologic subgroups: idiopathic (IPAH, 34%, 243), connective tissue disease (APAH-CTD, 29%, 210), Drugs & Toxins (11%, 80), congenital heart disease (APAH-CHD, 6%, 46), and CTEPH (5%, 37)

At enrollment, patients had NYHA functional class II (46%, 253/554) or III (42%, 233/554) symptoms

Common comorbidities were: Hypertension in Drugs & Toxins (51%, 41), CTEPH (49%, 18), IPAH (39%, 95), APAH-CTD (38%, 79 ); obstructive sleep apnea in APAH-CHD (17%, 8), Overweight/obesity among CTEPH (81%, 30) and Drugs & Toxins (75%, 60)

Mean 6-minute walking distance (6MWD) was highest for Drugs & Toxins (381.3 m , n=73) and lowest for APAH-CTD (301.8 m, n=189). Mean pulmonary arterial pressure (mPAP) was higher in APAH-CHD (48.6 mmHg, n=41) and Drugs & Toxins (47.9 mmHg, n=75) compared to APAH-CTD (40.6 mmHg, n=196) and CTEPH (38.6 mmHg, n=33). Mean pulmonary vascular resistance (PVR) was significantly higher in IPAH (366.7 dynes-sec/m5, n=212) vs. CTEPH (136.2 dynes-sec/m5, n=33). Mean diffusing capacity for carbon monoxide (DLCO), % predicted was lowest in CTD (40.6%, n=118) and IPAH (53.8%, n=155)


Overall cohort enrollment characteristics, including NYHA functional class II/III, reduced 6MWD (<400m), and elevated BNP, indicate a compromised group at intermediate risk for clinical progression. Continued evaluation will elucidate disease impact on survival, current clinical practices, and place for precision medicine.

Conference/Value in Health Info

2021-05, ISPOR 2021, Montreal, Canada

Value in Health, Volume 24, Issue 5, S1 (May 2021)




Clinical Outcomes, Epidemiology & Public Health, Health Service Delivery & Process of Care

Topic Subcategory

Clinical Outcomes Assessment, Disease Management, Treatment Patterns and Guidelines


Cardiovascular Disorders, Personalized and Precision Medicine, Rare and Orphan Diseases, Systemic Disorders/Conditions

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now